EHA 2022 | Outcomes of patients with newly diagnosed CRLF2-rearranged B-ALL
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, comments on the results of a study evaluating the long-term outcomes of patients with newly diagnosed CRLF2-rearranged B-cell acute lymphoblastic leukemia (B-ALL) treated with hyper-CVAD and mini-hyper CVD-based regimens with or without targeted therapies like inotuzumab ozogamicin and blinatumomab. Overall, the study showed that patients who received targeted therapies had a better relapse-free survival (RFS) and overall survival (OS) than patients who were only treated with hyper-CVAD, and further analyses demonstrated that treatment with targeted therapies led to more favorable outcomes after two years. In addition, transplantation appeared to improve survival in patients who had additional JAK2 mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
